How is muscle‑invasive bladder cancer staged using histopathology (HPE) and PET‑CT?

Muscle-Invasive Bladder Cancer Staging: HPE and PET-CT

Muscle-invasive bladder cancer is staged using the TNM system based on histopathology from transurethral resection (TUR) specimens, with CT chest/abdomen/pelvis as the standard imaging modality for complete staging, while PET-CT is not routinely recommended but may provide additional value in high-risk patients or for detecting distant metastases. 1, 2

Histopathology (HPE) Staging

The pathological assessment forms the foundation of MIBC staging:

• TUR specimen evaluation must include both superficial and deep tumor areas, sent separately to pathology, with mandatory sampling of the muscularis propria (detrusor muscle) to confirm muscle invasion 1, 3
• The pathology report must specify tumor grade (low vs. high), depth of invasion, and confirm presence of lamina propria and muscle tissue in the specimen 1, 2
• TNM classification is the standard staging system, with the 8th edition AJCC reclassifying N staging based on number of metastatic regional lymph nodes and designating common iliac nodes as regional (N3) 1

Critical Pathology Elements:

• Tumor size, focality, and presence of lymphovascular invasion have prognostic utility 4
• Variant histologic differentiation should be identified as it affects prognosis and treatment decisions 3
• Carcinoma in situ (CIS) is an adverse prognostic factor requiring documentation 5

Important caveat: Clinical staging via TUR has significant limitations—nearly 50% of patients are understaged preoperatively, with 31% clinical understaging at final cystectomy 3, 4. This occurs because TUR cannot detect microscopic perivesical fat invasion (T3a disease) 5.

Imaging Staging

Standard Imaging Protocol

CT chest/abdomen/pelvis with contrast is the standard imaging modality for MIBC staging 1, 2:

• CT demonstrates bulky wall thickening, perivesical extension, lymph node enlargement, and distant metastases effectively 1
• CT urography should be included to evaluate the entire urothelium, as 2-4% of patients develop synchronous upper tract disease 1, 6
• Common metastatic sites include lymph nodes, bone, lung, liver, and peritoneum 1

CT limitations: Cannot distinguish inflammatory post-treatment changes from tumor, cannot assess depth of bladder wall invasion, and cannot detect microscopic extravesical extension or metastases in normal-sized lymph nodes 1

MRI for Local Staging

MRI with VI-RADS (Vesical Imaging Reporting and Data System) is superior to CT for differentiating T1 from T2 tumors and assessing local invasion 2, 3:

• Multiparametric MRI shows 83% sensitivity and 90% specificity for detecting MIBC 3
• MRI is the best modality for detecting bladder cancer invasion of detrusor muscle, perivesical tissues, and adjacent organs 1
• Diffusion-weighted imaging (DWI) combined with T2-weighted sequences significantly improves staging accuracy 1

PET-CT Role

PET-CT is NOT routinely recommended for standard MIBC staging but has specific applications 2:

When PET-CT May Be Appropriate:

• High-risk patients (T3/T4 disease, hydronephrosis, or high-risk histological features) where it changed treatment plans in 27% of cases 7
• Detecting distant metastases: PET-CT can identify metastatic disease missed by conventional CT, particularly in lymph nodes and distant organs 7, 8
• Post-neoadjuvant chemotherapy restaging: Diagnostic accuracy improves markedly after chemotherapy (AUC 0.83 vs. 0.62 without chemotherapy), with 80% sensitivity and 93.8% NPV 9

PET-CT Limitations:

• Does not increase nodal staging accuracy beyond CT or MRI for routine staging 1, 4
• Moderate overall diagnostic accuracy (AUC 0.70) with good specificity (82.7%) but low sensitivity (57.1%) for lymph node metastases 9
• Urinary tracer excretion interferes with primary tumor assessment 10
• No consensus role in routine clinical staging 4

Emerging evidence: FDG-PET/CT can improve malignancy detection in subcentimeter lymph nodes compared to size-based criteria alone 1. Novel tracers like FAPI show promise, with [18F]F-FAPI-74 demonstrating 100% sensitivity for lymph node metastases using quantitative cutoffs 11.

Practical Staging Algorithm

1. Confirm muscle invasion via TUR with adequate muscle sampling
2. Bimanual examination under anesthesia (though 11% overstage and 31% understage) 3
3. CT chest/abdomen/pelvis with urography for standard staging 2
4. Consider MRI with VI-RADS if differentiation between T1 and T2 is uncertain or for better local staging 2, 3
5. Reserve PET-CT for:
   • High-risk features (T3/T4, hydronephrosis, variant histology)
   • Suspected distant metastases not clearly defined on CT
   • Restaging after neoadjuvant chemotherapy 9, 7

Key Pitfalls to Avoid

• Incomplete TUR specimens: Always ensure muscularis propria is included to avoid understaging 1, 2
• Relying solely on lymph node size: Metastases occur in normal-sized nodes; functional imaging may help 1, 9
• Overlooking hydronephrosis: Independent predictor of extravesical disease and poor outcomes 5
• Missing upper tract disease: Always include CT urography in staging protocol 1, 6